AtheroNova (OTCBB: AHRO) is an early stage biotech company focused on discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits. The Company's focus on compounds to reduce or eliminate atherosclerotic plaque deposits addresses the most lucrative segments of the multi-billion dollar prescription drug market: cardiovascular disease and stroke prevention.
Crystal Research Associates has released an executive overview of the company. The report includes investment highlights, executive overview, corporate growth strategy, intellectual property, company leadership, core story (Atherosclerosis, AtheroNova's AHRO-001, Corporate Agreements), competition, milestones, historical financial results, risks, recent events, and glossary.
See the full report below.